SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-009595
Filing Date
2023-05-12
Accepted
2023-05-12 16:05:47
Documents
76
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q adap-20230331x10q.htm   iXBRL 10-Q 1289455
2 EX-31.1 adap-20230331xex31d1.htm EX-31.1 9821
3 EX-31.2 adap-20230331xex31d2.htm EX-31.2 10564
4 EX-32.1 adap-20230331xex32d1.htm EX-32.1 6131
5 EX-32.2 adap-20230331xex32d2.htm EX-32.2 6113
  Complete submission text file 0001558370-23-009595.txt   5933225

Data Files

Seq Description Document Type Size
6 EX-101.SCH adap-20230331.xsd EX-101.SCH 47390
7 EX-101.CAL adap-20230331_cal.xml EX-101.CAL 53707
8 EX-101.DEF adap-20230331_def.xml EX-101.DEF 166258
9 EX-101.LAB adap-20230331_lab.xml EX-101.LAB 372563
10 EX-101.PRE adap-20230331_pre.xml EX-101.PRE 284999
70 EXTRACTED XBRL INSTANCE DOCUMENT adap-20230331x10q_htm.xml XML 1043228
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37368 | Film No.: 23915601
SIC: 2836 Biological Products, (No Diagnostic Substances)